New drug combo shows promise in hodgkin lymphoma battle
NCT ID NCT07171827
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This study tested a new drug combination (brentuximab vedotin plus AVD) against the standard treatment (ABVD) for people with advanced Hodgkin lymphoma. Sixty patients took part to see which approach worked better and had fewer side effects. The goal was to improve disease control and survival without using lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-CD30 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Helwan University
Helwan, 11795, Egypt
Conditions
Explore the condition pages connected to this study.